TY  - JOUR
T1  - Vardenafil for the treatment of raynaud phenomenon: A randomized, double-blind, placebo-controlled crossover study
AU  - Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S
Y1  - 2012/08/13
N1  - 10.1001/archinternmed.2012.2271
JO  - Archives of Internal Medicine
SP  - 1182
EP  - 1184
VL  - 172
IS  - 15
N2  - 
Raynaud phenomenon (RP) is common and occurs with severe symptoms, particularly in patients with connective tissue disease (CTD), in whom RP may lead to digital ulcerations and amputations.1- 2 Medical therapy in these patients remains unsatisfactory. Administration of phosphodiesterase type 5 (PDE5) inhibitors, which inhibit the degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, promote vasorelaxation and are a promising therapeutic approach. However, randomized controlled trials have yielded conflicting results.3 We previously had conducted an open-label study with vardenafil hydrochloride trihydrate in patients with RP as a proof of concept.4 Our objective was to confirm our findings in a double-blind, randomized, placebo-controlled trial.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.2271
UR  - http://dx.doi.org/10.1001/archinternmed.2012.2271
ER  -